Adimmune (TPE:4142) EPS without NRI: NT$-0.48 (TTM As of Dec. 2025)


TPE:4142 Adimmune Corp TPE:4142
56 GF Score
Price NT$17.65
GF Value NT$25.66
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Adimmune EPS without NRI?

Adimmune TPE:4142 56 EPS without NRI is NT$-0.48 as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 56/100 and a GF Value™ of NT$25.66 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,168 Biotechnology companies, Adimmune ranks worse than 85616.35% on this metric.

Adimmune's earnings per share without non-recurring items for the three months ended in Dec. 2025 was NT$0.59. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.48.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Adimmune's EPS without NRI or its related term are showing as below:

During the past 13 years, Adimmune's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 28.00% per year. The lowest was -2.10% per year. And the median was 3.40% per year.

TPE:4142's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.4
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Adimmune's EPS (Diluted) for the three months ended in Dec. 2025 was NT$0.52. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.57.

Adimmune's EPS (Basic) for the three months ended in Dec. 2025 was NT$0.52. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.57.


Adimmune  (TPE:4142) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Adimmune EPS without NRI Related Terms


Adimmune EPS without NRI Historical Data

* Premium members only.

The historical data trend for Adimmune's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune EPS without NRI Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.69 -0.59 -0.58 -0.48

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.53 -0.52 -0.01 0.59

TPE:4142 vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Adimmune's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adimmune PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adimmune's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Adimmune's PE Ratio without NRI falls into.


TPE:4142
56GF Score
Adimmune Corp TPE:4142
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of NT$-0.48 mean?
Adimmune (TPE:4142) has a EPS without NRI of NT$-0.48 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Adimmune and its competitors. According to the industry distribution chart, Adimmune ranks #999999 out of 1168 companies in the Biotechnology industry.
Is Adimmune's EPS without NRI too high?
Adimmune's current EPS without NRI is NT$-0.48. Based on the distribution chart, Adimmune ranks #999999 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adimmune has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adimmune ranks #999999 out of 1168 companies for EPS without NRI. This places Adimmune in the lower half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Adimmune and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adimmune's current EPS without NRI is NT$-0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.66, compared to a current price of NT$17.65 — trading 31.2% below its estimated fair value. The current EPS without NRI is NT$-0.48. Adimmune's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Adimmune (TPE:4142), the current EPS without NRI is NT$-0.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$17.65 is trading 31.2% below its estimated GF Value™ of NT$25.66. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • EPS without NRI: NT$-0.48
  • GF Value™: NT$25.66 vs. price of NT$17.65 (31.2% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
56GF Score

Get the complete analysis for TPE:4142

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.65
Price
NT$25.66
GF Value